Published on 12 Dec 2021 on Insider Monkey via Yahoo Finance
We at Insider Monkey have gone over 867 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Travere Therapeutics, Inc. (NASDAQ:TVTX) based on that data.
Travere Therapeutics, Inc. (NASDAQ:TVTX) shares haven't seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 25 hedge funds' portfolios at the end of September. Our calculations also showed that TVTX isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings). The level and the change in hedge fund popularity aren't the only variables you need to analyze to decipher hedge funds' perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That's why at the end of this article we will examine companies such as Prelude Therapeutics Incorporated (NASDAQ:PRLD), GrowGeneration Corp. (NASDAQ:GRWG), and Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) to gather more data points.
At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, lithium prices have more than doubled over the past year, so we go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. With all of this in mind let's take a look at the key hedge fund action regarding Travere Therapeutics, Inc. (NASDAQ:TVTX).
Start tracking your investments with StatfolioSign up for free